Wearable tech aims to track rare brain diseases from home

NCT ID NCT05956834

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether wearable sensors can reliably monitor movement problems in people with progressive supranuclear palsy (PSP) and related frontotemporal disorders. About 60 participants will wear pendant-like devices for 12 months to track their activity. The goal is to see if remote monitoring is feasible and could be used in future research or care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this could lead to better ways to track disease progression at home, making clinical trials and care more convenient for patients.
What could go wrong: This is a small, early observational study focused on feasibility, not treatment. The sensors may be uncomfortable or fail to capture meaningful data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study intends to enroll a diverse population of individuals representative of the general PSP population. There are no restrictions based upon race or ethnic origin. This study will recruit both male and female participants aged 40 years or older with a clinical diagnosis of possible or probable PSP phenotype as defined by the 2017 MDS criteria.

Ages

40 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of possible or probable PSP as defined by the 2017 MDS criteria * Fluent in reading and speaking English and capable of providing informed consent based on the principal investigator's judgement * Able to walk 10 feet unassisted at the time of initial enrollment * Must have a caregiver or study partner who is willing and able to assist with all study-related procedures Exclusion Criteria: * Any neurological, medical, or psychiatric condition that would preclude participation in study activities based on the investigator's judgment. * A history of frequent falls defined as more than 5 falls per month, or who require a walker to ambulate safely at baseline will not be eligible to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CBD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Corticobasal Degeneration corticobasal degeneration disorder familial spontaneous pneumothorax frontotemporal dementia Frontotemporal Lobar Degeneration progressive supranuclear palsy red-green color blindness semantic dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CBD Corticobasal degeneration Frontotemporal dementia Frontotemporal lobar degeneration FTD Progressive supranuclear palsy PSP

Wearable tech aims to track rare brain diseases from home

What the study statuses mean